Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients

[1] Podolsky DK(2002)Inflammatory bowel disease N Engl J Med 347 417-429

[2] Hanauer SB(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

[3] Feagan BG(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[4] Lichtenstein GR(2005)Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2462-2476

[5] Colombel JF(2013)Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease J Crohns Colitis 7 769-779

[6] Sandborn WJ(2009)Dermatological complications and safety of anti-TNF treatments Gut 58 1033-1039

[7] Rutgeerts P(2011)Adverse events during biological therapy: focusing on dermatological side effects Orv Hetil 152 212-220

[8] Rutgeerts P(2005)Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study Arthritis Res Ther 7 R666-R676

[9] Sandborn WJ(2007)Cutaneous side effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists Br J Dermatol 156 486-491

[10] Feagan BG(2011)Skin lesions in patients with inflammatory bowel disease treated with immunomodulators and/or anti-tumor necrosis factor J Crohns Colitis P223 5:106-1098

[1] Podolsky DK(2002)Inflammatory bowel disease N Engl J Med 347 417-429

[2] Hanauer SB(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

[3] Feagan BG(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[4] Lichtenstein GR(2005)Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2462-2476

[5] Colombel JF(2013)Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease J Crohns Colitis 7 769-779

[6] Sandborn WJ(2009)Dermatological complications and safety of anti-TNF treatments Gut 58 1033-1039

[7] Rutgeerts P(2011)Adverse events during biological therapy: focusing on dermatological side effects Orv Hetil 152 212-220

[8] Rutgeerts P(2005)Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study Arthritis Res Ther 7 R666-R676

[9] Sandborn WJ(2007)Cutaneous side effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists Br J Dermatol 156 486-491

[10] Feagan BG(2011)Skin lesions in patients with inflammatory bowel disease treated with immunomodulators and/or anti-tumor necrosis factor J Crohns Colitis P223 5:106-1098